AVACTA GROUP PLC — Board/Management Information 2025

Feb 4, 2025

National Storage Mechanism | Additional information

RNS Number : 7481V

Avacta Group PLC

04 February 2025

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Appointment of Joint Broker

LONDON and PHILADELPHIA - February 4, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Panmure Liberum Limited ("Panmure Liberum") as its joint broker with immediate effect. Panmure Liberum will work alongside Peel Hunt, the Company's Nominated Adviser and existing corporate broker.

-Ends-

For further information from Avacta, please contact:

Avacta Group plc Michael Vinegrad, Group Communications Director	avacta.com
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden / Patrick Birkholm	www.peelhunt.com
Panmure Liberum (Joint Broker) Emma Earl, Will Goode, Mark Rogers David Cox (Healthcare Specialist Sales)	www.panmureliberum.com
ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert	avacta@consilium-comms.com
Investor and Communications Contact Renee Leck THRUST Strategic Communications	www.thruststrategiccommunications.com
Media Contact Carly Scaduto Carly Scaduto Consulting	Carly@carlyscadutoconsulting.com

About Avacta  -  http://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPSSWESDEISEFE